3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Hepatocellular
42
Parkinson Disease 4, Autosomal Dominant Lewy Body
29
Carcinoma, Renal Cell
26
Endometrial Neoplasms
13
Melanoma
10
Neoplasms
8
Uterine Cervical Neoplasms
7
Cholangiocarcinoma
7
Biliary Tract Neoplasms
7
Liver Neoplasms
6
Thyroid Neoplasms
5
Stomach Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Neuroendocrine Tumors
5
Triple Negative Breast Neoplasms
4
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Esophageal Squamous Cell Carcinoma
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Thyroid Carcinoma, Anaplastic
3
Recurrence
3
Kidney Neoplasms
3
Esophageal Neoplasms
3
Diabetes Mellitus, Insulin-Dependent, 12
3
Carcinoma, Adenoid Cystic
3
Breast Neoplasms
3
Brain Neoplasms
3
Adenocarcinoma
3
Vulvar Neoplasms
2
Interventions
belzutifan
4
Everolimus
2
spartalizumab
1
palbociclib
1
lenvatinib
1
gallium Ga 68 dotatate
1
cabozantinib
1
Nivolumab
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
von Hippel-Lindau Disease
×
lenvatinib
×
1 year
×
Clear all
NCT07405164
2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3
Recruiting
450 enrolled